西维来司他治疗脓毒症诱导的急性呼吸窘迫综合征的疗效与安全性:基于疾病严重程度和治疗策略亚组的更新荟萃分析。
完整摘要 · 中文译文
目的:西维来司他钠水合物是一种选择性中性粒细胞弹性蛋白酶抑制剂,可减轻中性粒细胞介导的肺泡-毛细血管损伤,在一些东亚国家用于急性肺损伤/ARDS。我们评估了西维来司他在脓毒症诱导的急性呼吸窘迫综合征(ARDS)中的疗效和安全性,并探讨疾病严重程度、基线死亡风险和治疗背景是否会改变其死亡效应。 方法:我们检索了PubMed/MEDLINE、Embase、Cochrane CENTRAL、Web of Science、CNKI、万方和ClinicalTrials.gov,检索时间从数据库建库至2026年8月27日。符合条件的研究为成人脓毒症诱导的ARDS研究,比较含西维来司他的方案与除此之外可比的不含西维来司他的方案。仅纳入COVID-19队列、非脓毒性ARDS、无法分离出脓毒症亚组的混合病因研究,以及两组均接受西维来司他的比较研究被排除。主要结局为全因死亡率;次要结局包括氧合指数(P/F比值)、机械通气持续时间、ICU住院时间、器官功能评分、炎症标志物和不良事件。死亡率以比值比(OR)采用限制性最大似然法的随机效应模型进行合并;主要分析和研究设计分析采用Hartung-Knapp区间。本综述已在PROSPERO前瞻性注册。 结果:14项研究符合定性合成条件,10项研究(943例患者)提供了可提取的2×2死亡率数据。接受西维来司他的431例患者中死亡73例,对照组的512例中死亡125例。Sivel estat与较低的死亡率相关(OR=0.55,95% CI 0.36-0.84;I2 = 0%)。该信号在随机试验中持续存在(OR=0.37,95% CI 0.16-0.86;I2 = 0%)。研究水平的点估计在基线P/F < 100 mmHg且对照组死亡率 >30%的队列中显得更为有利;然而,交互作用检验无统计学显著性,且严重程度分析为生态学性质。留一法分析结果稳定。Egger检验未检出显著的小样本不对称性(P = 0.197),但检验效能有限。按IL-6、PCT、CRP或中性粒细胞弹性蛋白酶进行基线分层的治疗效果数据不可获得,无法进行定量的效应修饰分析。 结论:在一项更新的、病因学严格的证据合成中,西维来司他(sivelestat)与脓毒症诱导的ARDS死亡率降低相关,包括在随机试验中。严重低氧血症和高基线风险仍是可能的富集因素,但当前的整体证据不足以支持经过验证的表型指导用药规则。联合干预措施的报道稀少,且俯卧位通气、镇静、神经肌肉阻滞和类固醇背景因素所致的残余混杂无法排除。 系统综述注册:PROSPERO CRD420261541158。
完整摘要 · 英文原文
OBJECTIVE: Sivelestat sodium hydrate is a selective neutrophil elastase inhibitor that attenuates neutrophil-mediated alveolar-capillary injury and is used in some East Asian countries for acute lung injury/ARDS. We evaluated the efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome (ARDS) and explored whether disease severity, baseline mortality risk, and treatment background modify the mortality effect. METHODS: We searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, CNKI, Wanfang, and ClinicalTrials.gov from database inception to August 27, 2026. Eligible studies were adult studies of sepsis-induced ARDS comparing a sivelestat-containing regimen with an otherwise comparable regimen without sivelestat. COVID-19-only cohorts, non-septic ARDS, mixed-etiology studies without a separable sepsis subgroup, and comparisons in which both groups received sivelestat were excluded. The primary outcome was all-cause mortality; secondary outcomes included P/F ratio, duration of mechanical ventilation, ICU length of stay, organ-function scores, inflammatory markers, and adverse events. Mortality was pooled as odds ratios (ORs) using a random-effects model with restricted maximum likelihood; Hartung-Knapp intervals were used for the primary and study-design analyses. This review was prospectively registered in PROSPERO. RESULTS: Fourteen studies were eligible for qualitative synthesis, and 10 studies (943 patients) provided extractable 2 × 2 mortality data. Deaths occurred in 73/431 patients receiving sivelestat and 125/512 controls. Sivelestat was associated with lower mortality (OR=0.55, 95% CI 0.36-0.84; I2 = 0%). The signal persisted in randomized trials (OR=0.37, 95% CI 0.16-0.86; I2 = 0%). Study-level point estimates appeared more favorable in cohorts with baseline P/F < 100 mmHg and control mortality >30%; however, interaction tests were not statistically significant and severity analyses were ecological. Leave-one-out analyses were stable. Egger testing did not detect significant small-study asymmetry (P = 0.197), although power was limited. Baseline-stratified treatment effects by IL-6, PCT, CRP, or neutrophil elastase were unavailable for quantitative effect-modification analyses. CONCLUSIONS: In an updated and etiologically strict evidence synthesis, sivelestat was associated with lower mortality in sepsis-induced ARDS, including in randomized trials. Severe hypoxemia and high baseline risk remain plausible enrichment factors, but current aggregate evidence is insufficient to support a validated phenotype-guided prescribing rule. Co-intervention reporting was sparse, and residual confounding by prone positioning, sedation, neuromuscular blockade, and steroid background cannot be excluded. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420261541158.